One Million Patients Measured on the Neurolens Measurement Device

Neurolens announced that 1 million patients have been measured on the Neurolens Measurement Device, an eye tracking system that can identify eye misalignment as small as 0.01 prism diopters. Given the sharp acceleration in remote working and learning, optometrists have reported record numbers of patients experiencing the symptoms of eye misalignment such as headaches, eye strain, and neck pain. Neurolenses have been proven to alleviate these symptoms for over 93% of patients.

"While we have grown tenfold in the past 3 years, the unmet patient need remains massive," Pierre Bertrand, Neurolens CEO, said in a company news release. "Today we celebrate our one-millionth patient measured, a huge milestone for the organization. But with 80% of consumers experiencing symptoms of eyestrain according to The Vision Council's recent report 'FocusedinSights: Digital Habits 2022,' we are excited to continue bringing solutions to independent optometry to meet their needs. We are, first and foremost, in the business of patient outcomes."

In September of 2022, Neurolens raised $67 million from MVM Partners, Falcon Vision/KKR, Marshall Wace & Existing Investors. In late August of 2022, Inc. revealed that Neurolens had been recognized as the 28th fastest growing healthcare company on its annual Inc. 5000 list, a ranking of the fastest-growing private companies in America. Earlier in August, Neurolens released the results of a parallel arm study evaluating reading speed at baseline. The study revealed that after 7 days of lens wear, the average improvement in reading speed with Neurolenses was almost 70% higher than the improvement seen with other premium lens designs.

To learn more about Neurolens, visit our website at https://www.neurolens.com.